Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

AACR's achievement awards and lectureships recognize innovation in basic, translational, clinical, and epidemiological cancer research.

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding ...

In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company ...

本次Pre-NDA申请是基于TYKM1601202研究（ESAONA）的卓越结果。该研究是一项前瞻性、多中心、随机、活性对照的关键注册性研究，旨在评估甲磺酸艾多替尼片对比奥希替尼一线治疗NSCLC脑转移受试者的有效性和安全性。本研究由中国医学科学院肿瘤医院石远凯教授牵头，由山东省肿瘤医院、湖南省肿瘤医院等共计53家中心参研。该研究详情，请浏览clinicaltrial.gov，NCT ...

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharmaceutical company, issued a shareholder letter from CEO John Yu, M.D., outlining recen ...

Join us for a quick overview of BioNTech SE, a Biotechnology company whose shares moved 0.3% today. Here are some facts about ...

前言2025年欧洲肺癌大会（ELCC）于2025年3月26日至29日在法国巴黎举行，作为肺癌领域备受瞩目的国际学术盛会之一，ELCC公布了众多对临床诊疗决策有重要参考意义的临床试验结果。其中，一项评估奥希替尼联合赛沃替尼用于经奥希替尼治疗进展后存在M ...

编者按：2025年欧洲肿瘤内科学会乳腺癌年会（ESMO ...